Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Fox

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|September 27, 2016
Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
Saira Z Sheikh, Anne E Hammer, Norma Lynn Fox, et al.
Journal of Multidisciplinary Healthcare|July 29, 2024
Improving Craniofacial Team Collaboration: A Multicenter Interview Study of Effective Team MeetingsElexis Hollingsworth, Benjamin H Shields, Christopher Rutter, et al.
Augmentative and Alternative Communication (Baltimore, Md. : 1985)|November 23, 2006
Purposes of AAC device use for persons with ALS as reported by caregiversMelanie Fried-Oken, Lynn Fox, Marie T Rau, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|February 1, 2011
Natural disaster and crisis: lessons learned about cleft and craniofacial care from Hurricane Katrina and the West BankJohn A van Aalst, Ronald P Strauss, Lynn Fox, et al.
Clinical Pharmacology in Drug Development|May 11, 2016
Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy SubjectsHerbert Struemper, Thomas Murtaugh, Jane Gilbert, et al.
Chest|August 11, 2004
Quality of life after coronary artery bypass graft: results from the POST CABG TrialNorma Lynn Fox, Byron J Hoogwerf, Susan Czajkowski, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled StudyWilliam Stohl, Andreas Schwarting, Masato Okada, et al.
Lupus|July 9, 2021
10 Years of belimumab experience: What have we learnt?Roger A Levy, Tania Gonzalez-Rivera, Munther Khamashta, et al.
Journal of Clinical Psychopharmacology|April 14, 2020
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy AnalysisAnne C Andorn, Barbara R Haight, Sunita Shinde, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Clinical Pharmacology and Therapeutics|September 27, 2016
Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
Saira Z Sheikh, Anne E Hammer, Norma Lynn Fox, et al.
Journal of Multidisciplinary Healthcare|July 29, 2024
Improving Craniofacial Team Collaboration: A Multicenter Interview Study of Effective Team MeetingsElexis Hollingsworth, Benjamin H Shields, Christopher Rutter, et al.
Augmentative and Alternative Communication (Baltimore, Md. : 1985)|November 23, 2006
Purposes of AAC device use for persons with ALS as reported by caregiversMelanie Fried-Oken, Lynn Fox, Marie T Rau, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|February 1, 2011
Natural disaster and crisis: lessons learned about cleft and craniofacial care from Hurricane Katrina and the West BankJohn A van Aalst, Ronald P Strauss, Lynn Fox, et al.
Clinical Pharmacology in Drug Development|May 11, 2016
Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy SubjectsHerbert Struemper, Thomas Murtaugh, Jane Gilbert, et al.
Chest|August 11, 2004
Quality of life after coronary artery bypass graft: results from the POST CABG TrialNorma Lynn Fox, Byron J Hoogwerf, Susan Czajkowski, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled StudyWilliam Stohl, Andreas Schwarting, Masato Okada, et al.
Lupus|July 9, 2021
10 Years of belimumab experience: What have we learnt?Roger A Levy, Tania Gonzalez-Rivera, Munther Khamashta, et al.
Journal of Clinical Psychopharmacology|April 14, 2020
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy AnalysisAnne C Andorn, Barbara R Haight, Sunita Shinde, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Pageof 4